Agenda for Day 1 - Monday 9 November, 2026Monday, 9 November 2026

The traditional boundaries of drug discovery are dissolving. Increasingly, pharmaceutical companies are opening their compound libraries, data, and expertise to the global research community through open innovation platforms. Initiatives such as opnMe from Boehringer Ingelheim are reshaping how early scientific ideas move from academia and biotech into the pharmaceutical pipeline. In this Ecosystem Innovation session at BIO-Europe, leaders from pharma, biotech, and venture capital will explore how open collaboration models are accelerating discovery, de-risking early research, and creating new pathways for partnership. From accessing pharma compounds to co-developing breakthrough therapies, the panel will examine how these platforms are changing the rules of engagement across the life sciences ecosystem. Join this conversation to understand what open innovation means for the next generation of biotech founders, academic innovators, and investors—and how collaboration across sectors is shaping the future of drug discovery.

The Ones to Watch sessions at BIO-Europe spotlight emerging biotech companies, innovative startups, or groundbreaking projects that are poised to make a significant impact in the life sciences industry. These sessions provide a platform for showcasing cutting-edge ideas, novel technologies, and promising business models, offering attendees a glimpse into the future of biotech innovation. They are an excellent opportunity for investors, partners, and industry leaders to discover the next big players in the ecosystem.

If you would like to get involved, please contact partneringsponsorship@informa.com

Through their EMEA Advance Biotech Grant Program, Merck recognize standout emerging biotech companies and helps them navigate their path to commercialization. Delivered as a dynamic competition, five selected biotech companies will have the opportunity to pitch their breakthroughs to Merck's Grant representatives and the overall BIO-Europe audience.

Around the world, governments, investors, and industry leaders are racing to build the next great biotech hubs. From Boston and Basel to emerging ecosystems across Europe, Asia, and the Middle East, success depends on more than funding alone. Talent, infrastructure, translational science, and access to global pharma partners all play critical roles. Following a spotlight on emerging regional innovators, this panel at BIO-Europe brings together ecosystem builders from venture capital and pharma to research institutes and policy leaders to explore what it really takes to build a thriving life sciences cluster. What ingredients attract breakthrough startups? How can regions compete for talent and capital? And how can global collaboration ensure that innovation ecosystems remain connected rather than siloed? Join this discussion to understand how the next generation of biotech hubs will emerge and what it means for investors, startups, and partners worldwide.